Standout Papers
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol (2020)
- Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia (2020)
- NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial (2018)
- Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis (2021)
- Inclisiran and cardiovascular events: a patient-level analysis of phase III trials (2022)
Immediate Impact
5 by Nobel laureates 9 from Science/Nature 58 standout
Citing Papers
Emerging Delivery Systems for Enabling Precision Nucleic Acid Therapeutics
2025 Standout
Alzheimer’s Disease Detection Using Deep Learning on Neuroimaging: A Systematic Review
2024 Standout
Works of Mark Jaros being referenced
Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials
2012
Suitability of the Clinical Dementia Rating‐Sum of Boxes as a single primary endpoint for Alzheimer's disease trials
2011
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Mark Jaros | 1486 | 707 | 92 | 696 | 50 | 2.9k | |
| Heiner Greten | 3093 | 541 | 39 | 795 | 77 | 5.1k | |
| R. Dermot G. Neely | 929 | 475 | 5 | 230 | 51 | 1.9k | |
| Lisa R. Tannock | 1044 | 509 | 39 | 1234 | 79 | 3.2k | |
| R.P. Naoumova | 1523 | 219 | 8 | 529 | 50 | 2.4k | |
| Mieke D. Trip | 1732 | 335 | 27 | 714 | 70 | 3.6k | |
| Giacomo Ruotolo | 1366 | 958 | 10 | 854 | 90 | 4.2k | |
| G Turpin | 874 | 1136 | 101 | 448 | 127 | 3.1k | |
| Connie B. Newman | 1205 | 467 | 92 | 285 | 55 | 2.8k | |
| Kathleen Wyne | 960 | 245 | 19 | 556 | 62 | 2.4k | |
| Evan A. Stein | 2571 | 406 | 43 | 396 | 58 | 4.6k |
All Works
Loading papers...